EP2575820A4 - Darreichungsform mit kontrollierter freisetzung mit quetiapin - Google Patents

Darreichungsform mit kontrollierter freisetzung mit quetiapin

Info

Publication number: EP2575820A4
Authority: EP; European Patent Office
Prior art keywords: quétiapine; extended release; pharmaceutical form; pharmaceutical; extended
Prior art date: 2010-05-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP11785946.2A

Other languages

English (en)

French (fr)

Other versions

EP2575820A1 (de

Inventor

Ma David Wai Fung

Prashant Manohar Mandaogade

Naresh Talwar

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pharmascience Inc

Original Assignee

Pharmascience Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-05-27

Filing date

2011-05-27

Publication date

2014-01-08

2011-05-27 Application filed by Pharmascience Inc filed Critical Pharmascience Inc

2013-04-10 Publication of EP2575820A1 publication Critical patent/EP2575820A1/de

2014-01-08 Publication of EP2575820A4 publication Critical patent/EP2575820A4/de

Status Withdrawn legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

EP11785946.2A 2010-05-27 2011-05-27 Darreichungsform mit kontrollierter freisetzung mit quetiapin Withdrawn EP2575820A4 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CA2705685A CA2705685A1 (en)	2010-05-27	2010-05-27	Pharmaceutical dosage form containing an antipsychotic agent
PCT/CA2011/000620 WO2011147025A1 (en)	2010-05-27	2011-05-27	Controlled release dosage form comprising quetiapine

Publications (2)

Publication Number	Publication Date
EP2575820A1 EP2575820A1 (de)	2013-04-10
EP2575820A4 true EP2575820A4 (de)	2014-01-08

Family

ID=45003170

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP11785946.2A Withdrawn EP2575820A4 (de)	2010-05-27	2011-05-27	Darreichungsform mit kontrollierter freisetzung mit quetiapin

Country Status (4)

Country	Link
EP (1)	EP2575820A4 (de)
CA (2)	CA2705685A1 (de)
SG (1)	SG187172A1 (de)
WO (1)	WO2011147025A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014155387A1 (en) *	2013-03-24	2014-10-02	Tushar Patel	Extended release dosage forms of quetiapine salts

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005041935A1 (en) *	2003-10-21	2005-05-12	Alpharma, Inc.	Pharmaceutical formulations containing quetiapine
US20090317473A1 (en) *	2008-06-20	2009-12-24	Naringrekar Gandha V	Controlled-release formulations, method of manufacture, and use thereof
EP2153834A2 (de) *	2008-08-07	2010-02-17	Farmaprojects, S.A.	Pharmazeutische Zusammensetzungen mit anhaltender Freisetzung, die Quetiapinsalze umfassen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090035370A1 (en) *	2007-08-02	2009-02-05	Drugtech Corporation	Dosage form and method of use
US7794750B2 (en) *	2008-06-20	2010-09-14	Mutual Pharmaceutical Company, Inc.	Controlled-release formulations, method of manufacture, and use thereof

2010
- 2010-05-27 CA CA2705685A patent/CA2705685A1/en not_active Abandoned
2011
- 2011-05-27 EP EP11785946.2A patent/EP2575820A4/de not_active Withdrawn
- 2011-05-27 CA CA2800910A patent/CA2800910A1/en not_active Abandoned
- 2011-05-27 SG SG2013005178A patent/SG187172A1/en unknown
- 2011-05-27 WO PCT/CA2011/000620 patent/WO2011147025A1/en not_active Ceased

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005041935A1 (en) *	2003-10-21	2005-05-12	Alpharma, Inc.	Pharmaceutical formulations containing quetiapine
US20090317473A1 (en) *	2008-06-20	2009-12-24	Naringrekar Gandha V	Controlled-release formulations, method of manufacture, and use thereof
EP2153834A2 (de) *	2008-08-07	2010-02-17	Farmaprojects, S.A.	Pharmazeutische Zusammensetzungen mit anhaltender Freisetzung, die Quetiapinsalze umfassen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2011147025A1 *

Also Published As

Publication number	Publication date
SG187172A1 (en)	2013-02-28
CA2800910A1 (en)	2011-12-01
EP2575820A1 (de)	2013-04-10
CA2705685A1 (en)	2011-11-27
WO2011147025A1 (en)	2011-12-01

Legal Events

Date	Code	Title	Description
2013-03-08	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2013-04-10	17P	Request for examination filed	Effective date: 20121206
2013-04-10	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2013-09-04	DAX	Request for extension of the european patent (deleted)
2014-01-08	A4	Supplementary search report drawn up and despatched	Effective date: 20131209
2014-01-08	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 9/20 20060101ALI20131203BHEP Ipc: A61K 47/12 20060101ALI20131203BHEP Ipc: A61K 31/554 20060101AFI20131203BHEP Ipc: A61K 9/16 20060101ALI20131203BHEP Ipc: A61K 47/44 20060101ALI20131203BHEP Ipc: A61P 25/18 20060101ALI20131203BHEP
2014-01-10	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1183825 Country of ref document: HK
2017-01-10	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2017-04-14	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2017-05-17	18D	Application deemed to be withdrawn	Effective date: 20161201
2020-01-03	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1183825 Country of ref document: HK

Publication	Publication Date	Title
EP2646006A4 (de)	2014-06-25	Arzneimitteldarreichungsform
EP2345410A4 (de)	2014-12-03	Pharmazeutische zusammensetzung mit kontrollierter freisetzung
FR2959935B1 (fr)	2013-02-08	Forme pharmaceutique orale alcoolo-resistante
FR2948568B1 (fr)	2012-08-24	Formulation pharmaceutique
EP2385823A4 (de)	2014-02-12	Pharmazeutische suspension mit zweifacher freisetzung
EP2453877A4 (de)	2013-05-29	Arzneimittelträgerzusammensetzung mit verzögerter freisetzung
SMT201700008B (it)	2017-03-08	Composizione farmaceutica
EP2637696A4 (de)	2016-07-06	Zusammensetzungen mit verzögerter freisetzung
EP2823362A4 (de)	2016-11-09	Drucksystem
PT2637710T (pt)	2017-07-12	Formulações à base de ácido hialurónico
DK3246018T3 (da)	2022-01-17	Farmaceutisk sammensætning
EP2478923A4 (de)	2013-04-03	Knochenregenerierungsmittel mit gelatine
GT201200303A (es)	2014-04-29	Formulaciones farmacéuticas
EE201300005A (et)	2013-08-15	Ravimkoostis
EP2642979A4 (de)	2014-09-17	Pharmazeutische zusammensetzung
BRPI0921654A2 (pt)	2016-02-10	formulação farmacêutica
EP2815752A4 (de)	2015-07-29	Orale pharmazeutische zusammensetzung
EP2665471A4 (de)	2014-07-23	Gesteuert freigesetzte orale pharmazeutische dosierformen mit mgbg
HUE053623T2 (hu)	2021-07-28	Vegyületek és azok felhasználása
EP2575487A4 (de)	2013-11-27	Orale formulierungen aus bipolaren transkarotinoiden
EP2815753A4 (de)	2015-07-01	Orale pharmazeutische zusammensetzung
EP2306998A4 (de)	2011-06-15	Pharmazeutische formulierung
EP2687532A4 (de)	2014-08-13	Neues octahydrothienochinolinderivat, pharmazeutische zusammensetzung mit diesem derivat und verwendung davon
EP2465512A4 (de)	2013-02-20	Schmerzunterdrückende pharmazeutische zusammensetzung
PT2623096T (pt)	2019-05-30	Composição farmacêutica com libertação prolongada de trimetazidina